Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ALXO - ALX Oncology begins dosing in phase 2/3 trial of evorpacept in gastric cancer

ALXO - ALX Oncology begins dosing in phase 2/3 trial of evorpacept in gastric cancer

ALX Oncology Holdings Inc.
ALX Oncology (NASDAQ:ALXO) said the first patient was dosed in a  phase 2/3 ASPEN-06 trial evaluating its drug evorpacept and Eli Lilly's (NYSE:LLY) Cyramza (ramucirumab), added to trastuzumab and paclitaxel to treat patients with HER2-positive gastric cancer or gastroesophageal junction cancer who have progressed following treatment with HER2-targeted therapy and chemotherapy. About 450 adult patients will be enrolled in the study across both phases. The study follows the ongoing ASPEN-01 phase 1b trial which showed benefit in patients.

For further details see:

ALX Oncology begins dosing in phase 2/3 trial of evorpacept in gastric cancer
Stock Information
Company Name: ALX Oncology Holdings Inc.
Stock Symbol: ALXO
Market: NASDAQ
Website: alxoncology.com
Menu
ALXO ALXO Quote ALXO Short ALXO News ALXO Articles ALXO Message Board
Get ALXO Alerts

News, Short Squeeze, Breakout and More Instantly...